Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
BioNTech (Nasdaq: BNTX) announced that the minimum condition for its exchange offer for CureVac (Nasdaq: CVAC) has been satisfied after 184,071,410 CureVac shares (approximately 81.74% of issued and outstanding shares) were validly tendered before the initial period expired on Dec 3, 2025.
All validly tendered shares have been accepted and closing conditions for the post-offer reorganization are satisfied. BioNTech will deliver BioNTech ADSs (or cash in lieu of fractional ADSs) to tendering holders. A subsequent offering period runs until 12:01 a.m. ET on Dec 18, 2025. Non-tendering holders will receive ADSs (or cash) via reorganization and generally face a 15% Dutch dividend withholding tax; non-tendering shares will cease to be tradable post-reorganization.
BioNTech (Nasdaq: BNTX) announced key details and timing for its exchange offer for all outstanding CureVac shares (Nasdaq: CVAC).
The Offer is set to expire at 9:00 a.m. Eastern Time on December 3, 2025; CureVac shareholders are advised to tender by 6:00 p.m. ET on December 2, 2025 due to operational deadlines. The announced Exchange Ratio is 0.05363 BioNTech ADS per CureVac share, based on a 10‑day VWAP of BioNTech ADS of $101.88 (ending November 25, 2025).
At CureVac’s EGM on November 25, 2025, over 99.16% of votes cast approved the Offer‑related proposals. The Offer requires at least 80% valid tendered shares to close (may be reduced to 75% after four extensions). Non‑tendering holders who receive ADSs will generally face a 15% Dutch dividend withholding tax.
BioNTech (Nasdaq: BNTX) reported Q3 2025 revenue of €1,518.9 million, a year-over-year increase, and a Q3 net loss of €28.7 million (basic/diluted loss per share €0.12). Year-to-date revenues reached €1,962.5 million and cash, cash equivalents and securities totaled €16,704.9 million as of September 30, 2025. The company received a $1.5 billion payment from its Bristol Myers Squibb collaboration and raised full-year 2025 revenue guidance to €2.6–2.8 billion while lowering R&D, SG&A and capex guidance ranges. Operationally, interim Phase 2 pumitamig data in ES-SCLC showed encouraging anti-tumor activity and a manageable safety profile, and BioNTech launched a variant-adapted COVID-19 vaccine for the 2025/2026 season.
BioNTech (Nasdaq: BNTX) will host an Innovation Series R&D Day on Tuesday, November 11, 2025 at 09:00 a.m. EST (3:00 p.m. CET) in New York City. Company leadership will provide an overview of BioNTech’s strategy and clinical progress across its pipeline.
Investors, analysts and the public can join the event online via webcast; a replay will be available shortly after the event and archived on the company website for one year. Presentation slides will be posted on the Investor Relations “Events & Presentations” page at www.BioNTech.com.
BioNTech (Nasdaq: BNTX) will release its third quarter 2025 financial results on Monday, November 3, 2025. A live conference call and webcast for investors, analysts and the public will be held at 8:00 a.m. EST (2:00 p.m. CET) to discuss results and provide a corporate update.
Participants must register in advance to access telephone dial‑in numbers and a PIN; registration is recommended at least one day before the call. The slide presentation and live audio will be available on BioNTech's Investor Relations "Events & Presentations" page at www.BioNTech.com. A replay will be archived on the company website for 30 days after the call.
BioNTech (Nasdaq: BNTX) commenced a public exchange offer to acquire all outstanding CureVac shares (Nasdaq: CVAC) via an all‑stock transaction.
Each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs, implying an aggregate equity value of about $1.25 billion. The consideration is subject to a collar: 10‑day VWAP triggers of $126.55 and $84.37 set Exchange Ratios of 0.04318 and 0.06476 ADSs, respectively. The Offer expires at 9:00 a.m. NY on December 3, 2025, is conditioned on required regulatory approvals and at least 80% tender (may be reduced to 75% in certain cases), and includes a planned CureVac EGM on November 25, 2025.
BioNTech (NASDAQ: BNTX) has announced its second AI Day event, part of the company's Innovation Series, scheduled for October 1, 2025, at 9:00 AM EDT in London. The event will showcase BioNTech's artificial intelligence strategy and capabilities, particularly focusing on AI applications in their pipeline and internal processes.
The presentation will be accessible through a live webcast, with slides and recording available on BioNTech's Investor Relations website for one year following the event. This event marks a significant milestone in BioNTech's continued focus on AI development, following their acquisition of InstaDeep Ltd.
BioNTech (NASDAQ: BNTX) and Bristol Myers Squibb have revealed promising interim Phase 2 data for their PD-L1xVEGF-A bispecific antibody pumitamig in treating extensive-stage small cell lung cancer (ES-SCLC). The trial demonstrated remarkable efficacy with a 76.3% confirmed objective response rate and a 100% disease control rate.
Key results include median progression-free survival of 6.8 months and an impressive 56.7% mean tumor shrinkage, with 89.5% of patients achieving early tumor reduction. The treatment showed a manageable safety profile with only a 14% discontinuation rate. These results support the ongoing global Phase 3 ROSETTA LUNG-01 trial and pumitamig's potential as a new standard of care for ES-SCLC patients.
Pfizer (NYSE:PFE) and BioNTech have announced positive topline results from their Phase 3 clinical trial of the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula. The study involved 100 participants, including adults aged 65+ and those 18-64 with risk conditions for severe COVID-19.
The trial demonstrated that 14 days post-vaccination, participants showed at least a 4-fold increase in LP.8.1-neutralizing antibody titers compared to pre-vaccination levels. The safety profile remained consistent with previous studies, with no new safety concerns identified.
These findings support the recent FDA approval of the LP.8.1-adapted COVID-19 vaccine and reinforce its potential effectiveness against multiple circulating SARS-CoV-2 sublineages.
BioNTech (NASDAQ:BNTX) and Pfizer have received FDA approval for their LP.8.1-adapted monovalent COVID-19 vaccine COMIRNATY® for adults 65 and older, and individuals 5-64 years with high-risk conditions. The 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, selected based on FDA guidance to better match circulating strains.
Pre-clinical data shows the vaccine generates improved immune responses against multiple SARS-CoV-2 sublineages, including XFG and NB.1.8.1, compared to previous JN.1 and KP.2-adapted versions. Immediate shipping will begin to ensure widespread availability across U.S. pharmacies, hospitals, and clinics.
To date, 5 billion doses of the Pfizer-BioNTech COVID-19 vaccine have been distributed globally, maintaining a favorable safety and efficacy profile supported by extensive real-world evidence.